In this study, the researchers focused on creating a multicomponent “glycoprotein” by incorporating a fluorescent glycoprobe galactosyl dicyanomethylene-4H-pyran (GAL-DCM, Figure 17) and an anti-cancer drug (Maytansine, Figure 17) into the hydrophobic pockets of HSA. Here, GAL is linked to cancer.